Mounjaro is owned by Eli Lilly And Co.
Mounjaro contains Tirzepatide.
Mounjaro has a total of 4 drug patents out of which 0 drug patents have expired.
Mounjaro was authorised for market use on 13 May, 2022.
Mounjaro is available in solution;subcutaneous dosage forms.
Mounjaro can be used as mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Drug patent challenges can be filed against Mounjaro from 2026-05-13.
The generics of Mounjaro are possible to be released after 14 June, 2039.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US9474780||ELI LILLY AND CO||GIP and GLP-1 co-agonist compounds|| |
(12 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8734394||ELI LILLY AND CO||Automatic injection device with delay mechanism including dual functioning biasing member|| |
(7 years from now)
|US9402957||ELI LILLY AND CO||Automatic injection device with delay mechanism including dual functioning biasing member|| |
(8 years from now)
|US11357820||ELI LILLY AND CO||GIP/GLP1 agonist compositions|| |
(16 years from now)
|New Chemical Entity Exclusivity (NCE)||May 13, 2027|
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 2026-05-13
Market Authorisation Date: 13 May, 2022
Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Korea, Republic of
Moldova, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic